REGN Q3 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.7B+10.6% YoY

Gross Profit

$3.2B86.8% margin

Operating Income

$1.2B31.7% margin

Net Income

$1.3B36.0% margin

EPS (Diluted)

$11.54

QoQ Revenue Growth

+4.9%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.1B

Stock-Based Comp.

$225M

Balance Sheet

Total Assets

$37.4B

Total Liabilities

$8.1B

Stockholders' Equity

$29.3B

Cash & Equivalents

$2.0B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.7B	$3.4B	+10.6%
Gross Profit	$3.2B	$2.8B	+14.5%
Operating Income	$1.2B	$1.2B	-2.6%
Net Income	$1.3B	$1.0B	+33.0%

Revenue Segments

Product

$1.9B52%

Collaboration Revenue

$1.7B45%

Product and Service, Other

$114M3%